Status:
WITHDRAWN
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice
Lead Sponsor:
Bayer
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
The study is designed as non interventional to collect data on the safety especially, severe hypoglycemia or documented symptomatic hypoglycemic episodes and effectiveness of acarbose/metformin fixed-...
Eligibility Criteria
Inclusion
- Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.
- Willing to give informed consent for participating in this study
Exclusion
- Patients receiving anti-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be allowed \& recorded in case record form.
- Patient receiving acarbose/metformin fixed dose combination during 3-months prior to enrollment.
- Exclusion criteria should be read in conjunction with local product information
Key Trial Info
Start Date :
August 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01915264
Start Date
August 1 2015
End Date
March 1 2017
Last Update
April 25 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.